logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Today’s Highlights

Portola: Ignoring the Good News. Aimmune Therapeutic’s Drug AR101 Met Its Primary Efficacy Endpoint

Portola Pharmaceuticals and the CHMP’s Oral Explanations  for Andexanet Alfa and Betrixaban Portola (PTLA)   announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has communicated a  positive trend vote  on the Marketing Authorization Application (MAA)...

Read More

February 21, 2018

0

Why Alder Biopharmaceuticals Stock Gained Over 83%. See Also: Prohost Picked Stocks Outperforming in a Down Market Day

Migraine's Really Effective Treatments The years 2018 and 2019 could be called the years of migraine’s really effective treatments. Three Calcitonin-gene-related peptide ( CGRP ) monoclonal antibody drugs have been approved in 2018 and 2019. They are: Aimovig for Amgen...

Read More

September 16, 2019

0

Alnylam Reaches Prohost 2018 Target. Regeneron Negotiates a Lower Price for Praluent

Alnylam (ALNY)  announced that Sanofi Genzyme declined its opt-in for the development and commercialization of the RNAi product  lumasiran , an investigational RNAi therapeutic for the treatment of  Primary Hyperoxaluria Type 1 (PH1).  Based on this decision, Alnylam intends to...

Read More

March 13, 2018

0

ObsEva Announced Positive Results from Its Product Nolasiban for In Vitro Fertilization

FERTILITY Fertility is what guarantees the presence of humans on the planet Earth. The reproductive system in men and women are the engines of fertility that creates living beings. These important engines get disturbed in some people, which represents a...

Read More

February 27, 2018

0

Regeneron’s Product Dupixant is Shown to Improve the Management of Asthma

Regeneron’s (REGN)   pipeline products have still a lot of good news to announce. The latest is about its product Dupixant (dupilumab) which has already been FDA approved for atopic dermatitis. Now, there are reasons to believe that this drug...

Read More

March 6, 2018

0

Exelixis moves more products into clinical trials. Alnylam's product Givosiran demonstrates efficacy in Acute Hepatic Porphyria (AHP). Why investors have caused a stock selloff.

Thanks to abundant cabozantinib sales’ revenues Exelixis (EXEL) is advancing a new generation of its medicines with its new product XL092 entering clinical trials . The drug is a next-generation oral tyrosine kinase inhibitor that targets VEGF receptors & MET...

Read More

March 6, 2019

0

Heron Therapeutics’ Product HTX-011: Helping in the War Against Opioids. Why Regeneron Could Fiercely Rebound

What Do We Make of the Following Good News? HERON THERAPEUTICS Will HTX-011 Help in the War Against Opioids?  Heron Therapeutics (HRTX) , a commercial-stage biotechnology company announced positive results from its completed Phase 3 studies of the investigational agent ...

Read More

March 20, 2018

0

Gene therapy: Speeding down the road towards offering cures. A small firm might have some good news

We love to read news about gene therapy as it is the only possibility for curing diseases that no known treatment can halt or delay their progression. The attempts to use gene therapy failed ambitious researchers for several decades before...

Read More

March 12, 2019

0

Roche Checkpoint Inhibitor Conquers Squamous Non-Small-Cell Lung Cancer. See Also: Some Insight on Immunotherapy and More

In spite of their successes, Immuno-oncology products, which we still like to call immunotherapy for several reasons, are a work in progress. The most two highlighted approaches that enable the immune system to clear cancers are the  checkpoint inhibition  and...

Read More

March 21, 2018

0

Atara Allogeneic Product ATA188 Will Confirm Whether EBV Infecting B Cells Could Cause a Difficult to Treat Kind of MS

Atara Biotherapeutics ATA188 for MS Atara Biotherapeutics ( ATRA ) announced the presentation of initial efficacy data as well as updated safety results from its ongoing Phase 1 study of the firm’s product ATA188 for the treatment of a progressive...

Read More

September 17, 2019

0

  • Previous
  • 1
  • 2
  • ...
  • 69
  • 70
  • 71
  • ...
  • 172
  • 173
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy